Precipio Reports Strong 2025 Financial Results: Revenue, EBITDA, and Cash Flow Growth
Precipio, Inc. Announces Robust Preliminary 2025 Financial Results: Revenues Surge 30%, Positive EBITDA and Operating Cash Flow
Key Highlights from Precipio’s 2025 Preliminary Financial Report
- Revenues for 2025 soared to \$24.0 million, representing a substantial 30% year-over-year increase from \$18.5 million in 2024.
- Q4-2025 revenues reached \$6.7 million, up 23% from \$5.4 million in the same quarter of 2024.
- Adjusted EBITDA turned strongly positive at \$0.95 million for Q4-2025 and \$1.23 million for the full year 2025, a significant improvement from just \$0.40 million in Q4-2024 and a loss of \$1.5 million in 2024.
- Operating cash flow was positive at \$688,000 for 2025 (\$368,000 in Q4-2025), up from \$439,000 in 2024. Excluding unusual items, adjusted operating cash flow was \$727,000 for the year and \$617,000 in Q4 alone.
- Net Income swung to positive territory in Q4-2025 at \$0.5 million versus a net loss of \$0.4 million in Q4-2024.
- Shareholder value reportedly tripled during 2025, according to CEO Ilan Danieli.
Detailed Financial Performance and Reconciliation
Precipio’s preliminary, unaudited results for the year and quarter ended December 31, 2025, demonstrate the company’s accelerating commercial momentum. The following metrics are particularly noteworthy for investors:
Revenue Growth
- 2025 full-year revenues: \$24.0 million (up from \$18.5 million in 2024).
- Q4-2025 revenues: \$6.7 million (up from \$5.4 million in Q4-2024).
Profitability and Cash Flow
- Adjusted EBITDA: \$0.95 million for Q4-2025, \$1.23 million for the full year. This marks a major turnaround from 2024’s annual loss of \$1.5 million.
- Operating Cash Flow: Positive \$688,000 for 2025, with \$368,000 generated in Q4. Excluding one-off items (Change Healthcare transactions and COVID-related Employee Retention Credit), adjusted operating cash flow would be \$727,000 for the year and \$617,000 in Q4 alone.
- Net Income (GAAP): \$0.5 million in Q4-2025, compared to a loss of \$0.4 million in Q4-2024.
EBITDA and Adjusted EBITDA Breakdown (Q4-2025 vs. Q4-2024)
|
Q4-2025 (\$M) |
Q4-2024 (\$M) |
| Net Income/(Loss) (GAAP) |
0.5 |
(0.4) |
| Interest Expense, Net |
0.0 |
0.0 |
| Income Taxes |
0.0 |
0.0 |
| Depreciation |
0.1 |
0.1 |
| Amortization of Intangibles |
0.3 |
0.3 |
| EBITDA (non-GAAP) |
0.9 |
0.0 |
| Stock-Based Compensation Expense |
0.1 |
0.4 |
| Other Significant (Income) Expenses |
0.0 |
0.0 |
| Adjusted EBITDA (non-GAAP) |
1.0 |
0.4 |
Management Commentary and Strategic Implications
“Becoming an EBITDA and cash-flow positive business has a very important impact on how we manage the business. It allows us to now invest in growth projects that consider a longer-term perspective for the Company, rather than a constant focus on short-term cash burn considerations… 2025 was a great year for us, one where the business performed well, and shareholders saw their value triple. We are confident in our ability to continue to create this value.”
Precipio’s transformation to positive EBITDA and operating cash flow is highly significant, as it suggests the company is not only on sounder financial footing but is also positioned to invest in future growth initiatives without depending solely on external funding. The CEO’s remarks regarding a tripling of shareholder value in 2025 are particularly notable and may be price sensitive for current and prospective investors.
Additional Information for Shareholders
- Further details and an in-depth discussion of 2025 performance and 2026 outlook will be provided during a shareholder call in early April, after the filing of the 10-K annual report.
- All numbers reported are preliminary and unaudited, and subject to adjustment upon completion of the annual audit.
- Investors are encouraged to monitor the company’s website and social media channels for updates and material disclosures, as these may contain important information not disseminated elsewhere.
About Precipio
Precipio, Inc. (NASDAQ: PRPO) is a healthcare biotechnology company specializing in cancer diagnostics. With a mission to reduce cancer misdiagnosis, Precipio develops and commercializes proprietary diagnostic products and services that improve accuracy, laboratory workflow, and ultimately patient outcomes, while reducing healthcare costs. The company employs its technologies both in-house and for the broader laboratory community worldwide.
Forward-Looking Statements
This article contains forward-looking statements based on current expectations, estimates, and projections about Precipio’s operations, industry, financial condition, performance, and results. Actual outcomes may differ materially due to risks and uncertainties, including those discussed in Precipio’s filings with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these statements. Precipio undertakes no obligation to update any forward-looking statements, except as required by law.
Contact
For investor inquiries, please contact: [email protected] or call +1-203-787-7888 Ext. 523.
Disclaimer: This article is for informational purposes only and does not constitute financial advice or an offer to buy or sell any securities. All financial data are preliminary and unaudited. Investors should consult official filings and their own advisors prior to making investment decisions.
View Precipio, Inc. Historical chart here
